Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

IFN╬│-Induced IFIT5 Promotes Epithelial-to-Mesenchymal Transition in Prostate Cancer via miRNA Processing.

Lo UG, Pong RC, Yang D, Gandee L, Hernandez E, Dang A, Lin CJ, Santoyo J, Ma S, Sonavane R, Huang J, Tseng SF, Moro L, Arbini AA, Kapur P, Raj GV, He D, Lai CH, Lin H, Hsieh JT.

Cancer Res. 2019 Mar 15;79(6):1098-1112. doi: 10.1158/0008-5472.CAN-18-2207. Epub 2018 Nov 30.

PMID:
30504123
2.

Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy.

Menon JU, Kuriakose A, Iyer R, Hernandez E, Gandee L, Zhang S, Takahashi M, Zhang Z, Saha D, Nguyen KT.

Sci Rep. 2017 Oct 16;7(1):13249. doi: 10.1038/s41598-017-13320-4.

3.

MEK Is a Therapeutic and Chemopreventative Target in Squamous Cell Carcinoma.

Adelmann CH, Truong KA, Liang RJ, Bansal V, Gandee L, Saporito RC, Lee W, Du L, Nicholas C, Napoli M, Mino B, South AP, Proby CM, Leigh IM, Coarfa C, Flores ER, Tsai KY.

J Invest Dermatol. 2016 Sep;136(9):1920-1924. doi: 10.1016/j.jid.2016.05.110. Epub 2016 Jun 9. No abstract available.

4.

Noninvasive Staging of Kidney Dysfunction Enabled by Renal-Clearable Luminescent Gold Nanoparticles.

Yu M, Zhou J, Du B, Ning X, Authement C, Gandee L, Kapur P, Hsieh JT, Zheng J.

Angew Chem Int Ed Engl. 2016 Feb 18;55(8):2787-91. doi: 10.1002/anie.201511148. Epub 2016 Jan 22.

5.

The efficacy of immediate versus delayed antibiotic administration on bacterial growth and biofilm production of selected strains of uropathogenic Escherichia coli and Pseudomonas aeruginosa.

Gandee L, Hsieh JT, Sperandio V, Moreira CG, Lai CH, Zimmern PE.

Int Braz J Urol. 2015 Jan-Feb;41(1):67-77. doi: 10.1590/S1677-5538.IBJU.2015.01.10.

6.

The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.

Tsai YS, Lai CL, Lai CH, Chang KH, Wu K, Tseng SF, Fazli L, Gleave M, Xiao G, Gandee L, Sharifi N, Moro L, Tzai TS, Hsieh JT.

Oncotarget. 2014 Aug 15;5(15):6425-36.

7.

Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin.

Lai CH, Chang CS, Liu HH, Tsai YS, Hsu FM, Yu YL, Lai CK, Gandee L, Pong RC, Hsu HW, Yu L, Saha D, Hsieh JT.

Oncotarget. 2014 Jul 30;5(14):5523-34.

8.

Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.

Arbini AA, Guerra F, Greco M, Marra E, Gandee L, Xiao G, Lotan Y, Gasparre G, Hsieh JT, Moro L.

Oncogenesis. 2013 Dec 16;2:e82. doi: 10.1038/oncsis.2013.45.

9.

Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy.

Tumati V, Mathur S, Song K, Hsieh JT, Zhao D, Takahashi M, Dobin T, Gandee L, Solberg TD, Habib AA, Saha D.

Int J Oncol. 2013 May;42(5):1613-9. doi: 10.3892/ijo.2013.1858. Epub 2013 Mar 19.

10.

Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles.

Wadajkar AS, Menon JU, Tsai YS, Gore C, Dobin T, Gandee L, Kangasniemi K, Takahashi M, Manandhar B, Ahn JM, Hsieh JT, Nguyen KT.

Biomaterials. 2013 May;34(14):3618-25. doi: 10.1016/j.biomaterials.2013.01.062. Epub 2013 Feb 15.

PMID:
23419645

Supplemental Content

Loading ...
Support Center